Keros reports Q3 2026 results, dosing start in DMD trial and new bone program

Keros Therapeutics reported business updates and financial results for the quarter ended September 30, 2026, in a release dated November 5, 2026. In September 2026, Keros announced that the first patient had been dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.¹ The company said it expects to announce initial data from this trial in the first half of 2027.¹

Keros also disclosed progress on a nonclinical program. The company nominated KER-206, a novel ligand trap designed to bind select TGF-β ligands to regulate bone remodeling, from its nonclinical pipeline for further investigation.¹ In October 2026, Keros presented findings on a research version of the molecule, called RKER-206, at a scientific meeting of the American Society for Bone and Mineral Research. According to the company, through inhibition of these TGF-β ligands, KER-206 has the potential to increase bone mass and improve skeletal integrity in disorders characterized by pathological bone loss.¹

On financials, Keros reported net income of $14.2 million in the third quarter of 2026, compared with a net loss of $7.3 million in the third quarter of 2025, an increase the company attributed mainly to revenue recognized under its license agreement with Takeda.¹

Cash and cash equivalents stood at $259.5 million as of September 30, 2026, down from $287.4 million at the end of 2025.¹ Based on current operating assumptions, the company said this cash position should fund operations and capital expenditures into the second half of 2028.¹

Keros' pipeline also includes rinvatercept for amyotrophic lateral sclerosis and elritercept, which the company described as its most advanced candidate, aimed at treating certain blood disorders in patients with myelodysplastic syndrome and myelofibrosis.